Market Cap 1.01B
Revenue (ttm) 82.25M
Net Income (ttm) -20.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,061.00
Profit Margin -24.54%
Debt to Equity Ratio 0.04
Volume 422,500
Avg Vol 582,876
Day's Range N/A - N/A
Shares Out 47.50M
Stochastic %K 30%
Beta 1.82
Analysts Strong Sell
Price Target $31.22

Company Profile

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induc...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 425 402 1400
Fax: 425 402 1433
Address:
3303 Monte Villa Parkway, Suite 310, Bothell, United States
Rabinovich
Rabinovich Jun. 5 at 10:51 AM
$BLFS Fascinating, not a single post in more than 2 weeks. The management enrichment fraud continues in silence. I guess those involved don't mind. The entire cell and gene therapy sector - who theoretically are the customers of this fraud - have been literally obliterated in the last 2 years with several bankruptcies, not profitable companies trading below cash, and profitable businesses trading at 1-2 times current sales. This fraud, however, continues trading at 10-12 times sales with no growth and no profitabilty. Just lol.
1 · Reply
Chomo
Chomo May. 14 at 10:09 PM
$BLFS expanding down all moving averages on high volume can not be good for longs
0 · Reply
Rabinovich
Rabinovich May. 9 at 2:14 PM
$BLFS Lol, this fraud with its miserable quarterly revenues of $25M not even profitable is valued at MC of more than $1B. Management enrichment fraud.
0 · Reply
lecorb
lecorb May. 8 at 8:27 PM
$BLFS BioLife Solutions GAAP EPS of -$0.01 beats by $0.04, revenue of $23.9M beats by $1.68M
0 · Reply
PsychedStocks
PsychedStocks May. 8 at 11:50 AM
$TBRIF $MDXG $EMED $BLFS $MMAT Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin https://www.newsfilecorp.com/release/251233
0 · Reply
Stock__Shark
Stock__Shark May. 7 at 5:24 PM
0 · Reply
PsychedStocks
PsychedStocks May. 7 at 4:37 PM
$TBRIF Spinning off consumer product portfolio into separate public company by H1 2025 FDA 510K approval for Venowave VW5 unlocks Medicare/Medicaid reimbursement market Revolutionizing vascular health with innovative medical devices and nationwide distribution $MDXG $EMED $BLFS $MMAT
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 30 at 12:13 PM
$BLFS reports Q1 2025 results May 8th. Investors will watch for signs of revenue stabilization after last year's 43% drop. Improved gross margins (65.3%) and $95M cash cushion could soften the blow if guidance disappoints. High P/S ratio of 14.3 leaves little room for error. https://www.prnewswire.com/news-releases/biolife-solutions-to-report-first-quarter-2025-financial-results-and-business-update-on-may-8-2025-302441713.html
0 · Reply
jpad
jpad Apr. 25 at 9:23 AM
$BLFS how high does it go this this time
0 · Reply
jpad
jpad Apr. 4 at 5:42 PM
$BLFS buying
0 · Reply
Latest News on BLFS
BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:59 PM EDT - 6 weeks ago

BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript


BioLife Solutions Updates Earnings Call Information

May 8, 2025, 4:32 PM EDT - 6 weeks ago

BioLife Solutions Updates Earnings Call Information


BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:23 AM EST - 4 months ago

BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript


BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:41 PM EST - 8 months ago

BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript


BioLife Solutions Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 8 months ago

BioLife Solutions Reports Third Quarter 2024 Financial Results


BioLife Is Cleaning Ship

Aug 20, 2024, 3:51 PM EDT - 11 months ago

BioLife Is Cleaning Ship


BioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:50 PM EDT - 11 months ago

BioLife Solutions, Inc. (BLFS) Q2 2024 Earnings Call Transcript


BioLife Solutions Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:03 PM EDT - 11 months ago

BioLife Solutions Reports Second Quarter 2024 Financial Results


BioLife Solutions: A Complicated Tale

Nov 29, 2023, 3:06 PM EST - 1 year ago

BioLife Solutions: A Complicated Tale


BioLife Hit By An Inventory Correction

Aug 30, 2023, 8:58 AM EDT - 1 year ago

BioLife Hit By An Inventory Correction


BioLife Solutions, Inc. (BLFS) Q1 2023 Earnings Call Transcript

May 10, 2023, 9:30 PM EDT - 2 years ago

BioLife Solutions, Inc. (BLFS) Q1 2023 Earnings Call Transcript


BioLife Solutions Reports First Quarter 2023 Financial Results

May 10, 2023, 4:03 PM EDT - 2 years ago

BioLife Solutions Reports First Quarter 2023 Financial Results


BioLife Solutions: Capitalizing On The Future Of Biopreservation

Mar 28, 2023, 12:08 PM EDT - 2 years ago

BioLife Solutions: Capitalizing On The Future Of Biopreservation


BioLife Solutions Is Set To Finally Absorb Its Acquisitions

Mar 25, 2023, 7:51 AM EDT - 2 years ago

BioLife Solutions Is Set To Finally Absorb Its Acquisitions


BioLife Solutions, Inc. (BLFS) Q4 2022 Earnings Call Transcript

Mar 16, 2023, 9:55 PM EDT - 2 years ago

BioLife Solutions, Inc. (BLFS) Q4 2022 Earnings Call Transcript


Rabinovich
Rabinovich Jun. 5 at 10:51 AM
$BLFS Fascinating, not a single post in more than 2 weeks. The management enrichment fraud continues in silence. I guess those involved don't mind. The entire cell and gene therapy sector - who theoretically are the customers of this fraud - have been literally obliterated in the last 2 years with several bankruptcies, not profitable companies trading below cash, and profitable businesses trading at 1-2 times current sales. This fraud, however, continues trading at 10-12 times sales with no growth and no profitabilty. Just lol.
1 · Reply
Chomo
Chomo May. 14 at 10:09 PM
$BLFS expanding down all moving averages on high volume can not be good for longs
0 · Reply
Rabinovich
Rabinovich May. 9 at 2:14 PM
$BLFS Lol, this fraud with its miserable quarterly revenues of $25M not even profitable is valued at MC of more than $1B. Management enrichment fraud.
0 · Reply
lecorb
lecorb May. 8 at 8:27 PM
$BLFS BioLife Solutions GAAP EPS of -$0.01 beats by $0.04, revenue of $23.9M beats by $1.68M
0 · Reply
PsychedStocks
PsychedStocks May. 8 at 11:50 AM
$TBRIF $MDXG $EMED $BLFS $MMAT Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin https://www.newsfilecorp.com/release/251233
0 · Reply
Stock__Shark
Stock__Shark May. 7 at 5:24 PM
0 · Reply
PsychedStocks
PsychedStocks May. 7 at 4:37 PM
$TBRIF Spinning off consumer product portfolio into separate public company by H1 2025 FDA 510K approval for Venowave VW5 unlocks Medicare/Medicaid reimbursement market Revolutionizing vascular health with innovative medical devices and nationwide distribution $MDXG $EMED $BLFS $MMAT
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 30 at 12:13 PM
$BLFS reports Q1 2025 results May 8th. Investors will watch for signs of revenue stabilization after last year's 43% drop. Improved gross margins (65.3%) and $95M cash cushion could soften the blow if guidance disappoints. High P/S ratio of 14.3 leaves little room for error. https://www.prnewswire.com/news-releases/biolife-solutions-to-report-first-quarter-2025-financial-results-and-business-update-on-may-8-2025-302441713.html
0 · Reply
jpad
jpad Apr. 25 at 9:23 AM
$BLFS how high does it go this this time
0 · Reply
jpad
jpad Apr. 4 at 5:42 PM
$BLFS buying
0 · Reply
jpad
jpad Mar. 31 at 7:22 PM
$BLFS what happened!!
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 27 at 5:37 PM
$BLFS Digging the cell therapy play. BioLife's strategic pivot looks promising - higher margins, focused biz model. Cell Processing segment showing real strength. Watching for continued growth in CGT market. Might take a small position to play the trend. notable article: https://beyondspx.com/article/biolife-solutions-inc-nasdaq-blfs-a-transformative-shift-toward-enabling-cell-and-gene-therapies
0 · Reply
stockpicker63
stockpicker63 Mar. 27 at 5:30 PM
Stocks to watch today! $MUSA, $FRME, $BLFS, $FUL .
1 · Reply
jpad
jpad Mar. 26 at 10:12 AM
$BLFS why don’t they people manipulating this stock let it go up to $30
0 · Reply
JarvisFlow
JarvisFlow Mar. 6 at 11:00 AM
HC Wainwright & Co. has updated their rating for BioLife Solutions ( $BLFS ) to Buy with a price target of 30.
0 · Reply
Rabinovich
Rabinovich Mar. 5 at 9:48 PM
$BLFS This fraud is truly amazing. Pathetic $100M annual revenues, not really growing, has never been profitable, insiders selling shares all the time as soon as they vest and valued at $1.2b! Basically, this is a management enrichment vehicle.
2 · Reply
jParkz
jParkz Mar. 3 at 5:30 PM
News Article $BLFS BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results https://marketwirenews.com/news-releases/biolife-solutions-reports-fourth-quarter-and-full-ye-6987435930418214.html $BLFS
0 · Reply
DonCorleone77
DonCorleone77 Mar. 3 at 12:14 PM
$BLFS BioLife Solutions sees FY25 revenue $95.5M-$99M, consensus $95.46M
0 · Reply
DonCorleone77
DonCorleone77 Mar. 3 at 12:12 PM
$BLFS BioLife Solutions reports Q4 GAAP cont ops EPS (4c), consensus (6c) Reports Q4 revenue $22.7M, consensus $21.73M. Roderick de Greef, Chairman and CEO, commented, "This past year was a pivotal one for BioLife as we cemented our position as a leading pure play enabler of cell and gene therapies. We delivered five consecutive quarters of revenue growth in our cell processing platform, exceeding expectations and outperforming our raised full year guidance. At the same time, we remained focused on optimizing our portfolio - divesting non-core product lines to drive gross margin and adjusted EBITDA margin expansion from continuing operations. This work culminated in the completed sales of our freezer and biostorage businesses, bolstering our year-end cash position to more than $100 million to fuel our growth objectives. "With this foundation in place, we enter 2025 with streamlined operations focused on our proprietary, high-growth, high-margin products, positioning us to deliver continued revenue growth and profitability. We expect 2025 cell processing revenue to grow 18% to 21%, a meaningful acceleration over 2024, and we see a significant opportunity to deepen relationships with our biopreservation customers, leveraging cross-selling to increase adoption of our broader cell processing product lines. By ultimately integrating these tools into approved therapies, we have the potential to increase our revenue per dose by two to three-fold compared to our biopreservation media alone. Our focus remains on strategically enhancing our cell processing portfolio, both organically and inorganically, to strengthen our market leadership and continue delivering long-term value for our stakeholders," added de Greef.
0 · Reply
jpad
jpad Feb. 21 at 12:23 PM
$BLFS great stock to play Upside and downs. But someday it will go up and up might not get the down Let’s go to $35
1 · Reply
jpad
jpad Feb. 19 at 2:41 AM
$BLFS let’s get to $30
0 · Reply
WhisperNumber
WhisperNumber Feb. 12 at 8:05 PM
$TXG #earnings after close, the expectation from the WhisperNumber community is -$0.28, 2c ahead of analyst estimates. Implied move +/-12.9%. https://www.whispernumber.com/wr_alerts.jsp #options #trade $FTRE $EVO $BLFS
0 · Reply